Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RXI
|
|||
| Former ID |
DAP001187
|
|||
| Drug Name |
Hydrocortamate
|
|||
| Synonyms |
Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Approved | [1] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H41NO6
|
|||
| Canonical SMILES |
CCN(CC)CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)O
|
|||
| InChI |
1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1
|
|||
| InChIKey |
FWFVLWGEFDIZMJ-FOMYWIRZSA-N
|
|||
| CAS Number |
CAS 76-47-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:50851
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class II | ||||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Regulation of Androgen receptor activity | ||||
| AP-1 transcription factor network | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| SIDS Susceptibility Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Endoderm Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010554. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.